Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 353

    1.

    Prevention of breast cancer using selective oestrogen receptor modulators (SERMs).

    Powles TJ.

    Breast Cancer Res. 2006;8(5):111.

    PMID:
    17049068
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.

    Martino S, Costantino J, McNabb M, Mershon J, Bryant K, Powles T, Secrest RJ.

    Oncologist. 2004;9(2):116-25. Review.

    PMID:
    15047916
    [PubMed - indexed for MEDLINE]
    Free Article
    3.

    Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.

    Ganz PA, Land SR.

    Menopause. 2008 Jul-Aug;15(4 Suppl):797-803. Review.

    PMID:
    18596601
    [PubMed - indexed for MEDLINE]
    4.

    The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.

    Bevers TB.

    J Natl Compr Canc Netw. 2007 Sep;5(8):719-24. Review.

    PMID:
    17927929
    [PubMed - indexed for MEDLINE]
    5.

    The endocrine prevention of breast cancer.

    Howell A.

    Best Pract Res Clin Endocrinol Metab. 2008 Aug;22(4):615-23. Review.

    PMID:
    18971122
    [PubMed - indexed for MEDLINE]
    6.

    Prevention of breast cancer using SERMs.

    Powles TJ.

    Adv Exp Med Biol. 2008;630:232-6. Review.

    PMID:
    18637495
    [PubMed - indexed for MEDLINE]
    7.

    Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention.

    Zujewski J.

    Environ Mol Mutagen. 2002;39(2-3):264-70. Review.

    PMID:
    11921197
    [PubMed - indexed for MEDLINE]
    8.

    Endocrine prevention of breast cancer using selective oestrogen receptor modulators (SORMs).

    Lo SS, Vogel VG.

    Best Pract Res Clin Endocrinol Metab. 2004 Mar;18(1):97-111. Review.

    PMID:
    14687600
    [PubMed - indexed for MEDLINE]
    9.

    Prevention of hormone-related cancers: breast cancer.

    Dunn BK, Wickerham DL, Ford LG.

    J Clin Oncol. 2005 Jan 10;23(2):357-67. Review.

    PMID:
    15637398
    [PubMed - indexed for MEDLINE]
    10.

    The MORE trial: multiple outcomes for raloxifene evaluation--breast cancer as a secondary end point: implications for prevention.

    Dickler MN, Norton L.

    Ann N Y Acad Sci. 2001 Dec;949:134-42.

    PMID:
    11795345
    [PubMed - indexed for MEDLINE]
    11.

    Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.

    Jordan VC, Gapstur S, Morrow M.

    J Natl Cancer Inst. 2001 Oct 3;93(19):1449-57. Review.

    PMID:
    11584060
    [PubMed - indexed for MEDLINE]
    Free Article
    12.

    Chemoprevention of breast cancer.

    Thomsen A, Kolesar JM.

    Am J Health Syst Pharm. 2008 Dec 1;65(23):2221-8. Review.

    PMID:
    19020189
    [PubMed - indexed for MEDLINE]
    13.

    Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

    Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project (NSABP).

    JAMA. 2006 Jun 21;295(23):2727-41. Epub 2006 Jun 5. Erratum in: JAMA. 2006 Dec 27;296(24):2926. JAMA. 2007 Sep 5;298(9):973.

    PMID:
    16754727
    [PubMed - indexed for MEDLINE]
    14.

    Breast cancer prevention with selective estrogen receptor modulators: a perspective.

    Pritchard KI.

    Ann N Y Acad Sci. 2001 Dec;949:89-98. Review.

    PMID:
    11795385
    [PubMed - indexed for MEDLINE]
    15.

    Anti-oestrogenic chemoprevention of breast cancer-the need to progress.

    Powles TJ.

    Eur J Cancer. 2003 Mar;39(5):572-9. Review.

    PMID:
    12628835
    [PubMed - indexed for MEDLINE]
    16.

    Recent results from clinical trials using SERMs to reduce the risk of breast cancer.

    Vogel VG.

    Ann N Y Acad Sci. 2006 Nov;1089:127-42.

    PMID:
    17261762
    [PubMed - indexed for MEDLINE]
    17.

    [Specific estrogen receptor modulators (SERMs)].

    Trémollières F, Lopes P.

    Presse Med. 2002 Sep 7;31(28):1323-8. Review. French.

    PMID:
    12355995
    [PubMed - indexed for MEDLINE]
    18.

    Raloxifene (Evista) for breast cancer prevention in postmenopausal women.

    [No authors listed]

    Med Lett Drugs Ther. 2006 May 8;48(1234):37.

    PMID:
    16685245
    [PubMed - indexed for MEDLINE]
    19.

    Breast cancer chemoprevention.

    Rosenbaum Smith SM, Osborne MP.

    Am J Surg. 2000 Oct;180(4):249-51. Review.

    PMID:
    11113429
    [PubMed - indexed for MEDLINE]
    20.

    SERMs for the treatment and prevention of breast cancer.

    Swaby RF, Sharma CG, Jordan VC.

    Rev Endocr Metab Disord. 2007 Sep;8(3):229-39. Review.

    PMID:
    17440819
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk